Editor’s note: This article is produced in cooperation with Merck Holding (China).

Twelve finalists stood out from more than 100 projects from around the world, demonstrating their excellence in the global arena.

The panel included: Jerry Li, director of cross-sector innovation collaboration, Merck Innovation Hub; Mark Zhang, head of strategy & business operations China R, Merck Serono (Beijing) Pharmaceutical R Guo Mingfei, head of diagnostics business in China, Merck Chemicals (Shanghai); Poon Hong Wa, manager of Merck Accelerator Germany, Merck KGaA; as well as three other external professionals.

Malignant neoplasms are among the leading cause of morbidity and mortality in China, and although PD-L1 drugs have made progress in the treatment of cancer, there are still some problems such as low efficiency and long-term use drug resistance.

As a result, the team refined and developed PD-L1, which can reduce both intracellular and extracellular PD-L1.

This drug is expected to be a new class of tumour immunotherapy precursor with significant potential value in follow-up drug development and optimization.

The text above is a summary, you can read full article here.